The Roots Analysis team is putting in its best effort to offer our clients / readers a reliable source of information, regarding how the pharmaceutical and biotech sectors are coping in the midst of the COVID-19 pandemic. Our intention is to generate realistic insights, based on a variety of factors, which are anticipated to influence both prevalent and future market dynamics. Reach out to us for any help.

Novel Vaccine Delivery Devices Market, 2019-2030 [COVID-19 SERIES]

  • Lowest Price Guaranteed From USD 4,499

  • Published
    November 2019

  • Pages
    528

  • View Count
    3216

Example Insights

Novel Vaccine Delivery Devices Market, 2019-2030 -Context Novel Vaccine Delivery Devices Market, 2019-2030 -Type of delivery devices 	Novel Vaccine Delivery Devices Market, 2019-2030 -Market Landscape
Novel Vaccine Delivery Devices Market, 2019-2030 -Stages of development Novel Vaccine Delivery Devices Market, 2019-2030 -Device competitiveness analysis Novel Vaccine Delivery Devices Market, 2019-2030 -Likely drug candidates
Novel Vaccine Delivery Devices Market, 2019-2030 -Partnerships & Collarborations Novel Vaccine Delivery Devices Market, 2019-2030 -Swot Analysis Novel Vaccine Delivery Devices Market, 2019-2030 -Futuer forecast

 

Overview

[COVID-19 SERIES] According to experts, the global vaccines market is anticipated to generate revenues worth USD 100 billion by 2025. Data presented by the WHO indicates that the current global vaccination coverage is nearly 85%; this is believed to be responsible for preventing close to three million deaths from diseases, such as diphtheria, tetanus, whooping cough and measles. Recent global immunization records indicate that more than 115 million children were immunized against diphtheria, tetanus and pertussis in 2018. Given the rate at which the global population is growing, the demand for vaccines is likely to increase significantly. However, biopharmaceutical developers are plagued by concerns related to storage and handling of such preventive / therapeutic products. One commonly reported issue is related to vaccine administration. Despite the success of conventional delivery approaches, which rely on the intramuscular and subcutaneous routes of administration, the present scenario dictates that further improvements are required in order to deal with challenges related to large scale immunization initiatives. Some of the commonly reported disadvantages of the conventional (parenteral) mode of delivery include pain during administration, risk of cross contamination, needlestick injuries, and inaccurate dosing. 

Of late, there has been an evident shift in interest to non-invasive immunization methods, which include oral, intranasal and transdermal modes of administration. Currently, many biopharmaceutical companies and clinical research institutes are engaged in the development of novel vaccine delivery systems, taking into consideration the specific requirements of large scale immunization initiatives. As a result, significant efforts have been put into the development of drug delivery technologies / devices, such as microneedle patches, electroporation-based needle free injection systems, jet injectors, inhalation-based delivery systems, biodegradable implants and certain novel types of oral delivery systems. It is worth highlighting that most of the aforementioned systems are specifically being designed to facilitate pain-free administration of vaccines and allow self-administration. Additionally, these novel vaccine delivery devices can play an important role in vaccination during the event  of disease outbreaks / pandemics (such as the one being faced due to the novel coronavirus / COVID-19), where medical centers may not be equipped to deal with large scale immunization campaigns. Vaccine developers are also attempting to devise ways to make such products more stable so as to eliminate the need for cold chain in transporting such products. Given the pace of innovation in this field, it is anticipated that the novel vaccine delivery devices market is likely to witness radical changes in the coming years. 

Scope of the Report

The “Novel Vaccine Delivery Devices Market, 2019-2030” report features an extensive study of the current landscape and the likely future opportunities associated with novel vaccine delivery devices, over the next 10-12 years. Amongst other elements, the report includes:

  • A detailed assessment of the overall novel vaccine delivery devices market landscape, featuring an elaborate list of device developers and analysis based on a number of relevant parameters, such as year of establishment, company size, geographical location, type of device (autoinjectors, microneedle patches, jet injectors, dry powder inhalers, microinjectors, nasal delivery systems, pen injectors, biodegradable implants, electroporation-based needle free injection systems and novel oral delivery systems), route of administration (subcutaneous, transdermal, intramuscular, intradermal, inhalation, intranasal, and oral), drug delivery mechanism (mechanical, electrical and miscellaneous), nature of vaccine administration (invasive and non-invasive), speed of administration (fast, moderate and slow), self- administration potential, provisions for audio / visual feedback, device usability (disposable and reusable), type of needle (needleless, fixed needle, detachable needle, and hidden needle), and current development status of novel vaccine delivery systems (preclinical / discovery, clinical and marketed).
  • A detailed competitiveness analysis of novel vaccine delivery devices, taking into consideration the supplier power (based on the year of establishment of developer company) and key product specifications (such as route of administration, device usability, drug delivery mechanism, availability of needle safety system, speed of administration, self-administration potential, provisions for audio / visual feedback, nature of administration, cold chain requirement and current status of development).
  • An analysis evaluating the effectiveness of various vaccines delivery devices in order to compare their respective strengths and capabilities based on a variety of relevant parameters, such as type of active ingredient, dosage form, route of administration, target disease indication and target patient population.
  • A detailed list of marketed and pipeline vaccine candidates that are anticipated to be developed in combination with novel vaccine delivery devices in the near future, featuring analysis based on parameters, such as type of active ingredient, dosage form, route of administration, target disease indication and target patient population. 
  • Elaborate profiles of prominent product developers engaged in this domain; each profile features a brief overview of the company, its financial information (if available), information on its product portfolio, recent developments and an informed future outlook.
  • An analysis of recent collaborations and partnership agreements inked in this domain since 2014, including details of deals that were / are focused on novel vaccine delivery devices. The partnerships captured in the report were analyzed on the basis of year of establishment, type of agreement, type of device, type of vaccine, type of active ingredient and target disease indication.
  • A discussion on important, industry-specific trends, key market drivers and challenges, under a comprehensive SWOT framework, featuring a qualitative Harvey ball analysis that highlights the relative impact of each SWOT parameter on the overall market.

One of the key objectives of the report was to estimate the existing market size and assess potential future growth opportunities for novel vaccine delivery devices. Based on various parameters, such as number of marketed / pipeline products, price of devices (for commercially available products only) and estimated annual adoption rate, we have developed an informed estimate on the likely evolution of the market over the period 2019-2030. In addition, we have provided the likely distribution of the current and forecasted opportunities across [A] type of device (electroporation-based needle free injection systems, oral delivery systems, nasal delivery systems, jet injectors, microneedle patches and microinjectors), [B] route of administration (oral, intramuscular, intranasal, intradermal and subcutaneous), [C] type of vaccine (Bivalent Oral Polio Vaccine, BCG Vaccine, DTP-HepB-Hib Vaccine, Pneumococcal Conjugate Vaccine, Influenza Vaccine, Measles Vaccine, Tetanus-Diphtheria Vaccine and Others) and [D] key geographical regions (North America, Europe, Asia and rest of the world). In order to account for future uncertainties and to add robustness to our model, we have provided three market forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry’s growth.

The opinions and insights presented in the report were influenced by discussions held with senior stakeholders in the industry. The report features detailed transcripts of interviews held with the following industry stakeholders:

  • Michael Schrader, Chief Executive Officer and Founder, Vaxess Technologies
  • Mikael Ekstrom and Roger Lassing, Vice President, Business Development, Iconovo
  • Henry King, Market Intelligence and Business Development Manager, Innoture

All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

Contents

Chapter Outlines

Chapter 2 provides an executive summary of the insights captured in our research. It offers a high-level view on the current scenario within the novel vaccine delivery devices market and describes its evolution in the short-mid term and long term.

Chapter 3 provides a general introduction to vaccines along with information on classification of such preventive / therapeutic products. It also includes an overview of the various expression systems used in the development and manufacturing of vaccines and a discussion on various routes of administration. It features brief descriptions of various novel vaccine delivery devices and concludes with a discussion on the existing challenges and future trends that are likely to impact this emerging market segment.

Chapter 4 provides a detailed overview of the overall landscape of novel vaccine delivery devices that are developed / being developed for administration of various vaccines. It features an in-depth analysis of the devices, based on a number of parameters, such as details on type of device (autoinjectors, microneedle patches, jet injectors, dry powder inhalers, microinjectors, nasal delivery systems, pen injectors, biodegradable implants, electroporation-based needle free injection systems and novel oral delivery systems), route of administration (subcutaneous, transdermal, intramuscular, intradermal, inhalation, intranasal, and oral), drug delivery mechanism (mechanical, electrical and miscellaneous), nature of vaccine administration (invasive and non-invasive), speed of administration (fast, moderate and slow), self-administration potential, provisions for audio / visual feedback, device usability (disposable and reusable), type of needle (needleless, fixed needle, detachable needle, and hidden needle), and current development status of novel vaccine delivery systems (preclinical / discovery, clinical and marketed). In addition, the chapter provides information on drug developer(s), highlighting year of establishment, location of headquarters and strength of employee base. 

Chapter 5 features a product competitiveness analysis of novel vaccine delivery devices, based on the supplier power and product specifications. The analysis was designed to enable stakeholder companies to compare their existing capabilities within and beyond their respective peer groups and identify opportunities to achieve a competitive edge in the industry.

Chapter 6 provides detailed assessment to evaluate the effectiveness of various vaccines delivery devices to compare their strengths and capabilities for vaccine administration; the analysis is based on a variety of relevant parameters, such as type of active ingredient, dosage form, route of administration, target disease indication and target patient population.

Chapter 7 presents a list of marketed and pipeline vaccines that are likely to be considered for delivery via novel vaccine delivery devices in the future. The list was compiled considering various parameters, such as type of active ingredient, dosage form, route of administration, target disease indication and target patient population.  For the purpose of this analysis, we collated a list of over 490 marketed and clinical vaccines. The likelihood of delivery via novel vaccine delivery devices in the future was estimated using the weighted average of the aforementioned parameters. 

Chapter 8 provides detailed profiles of key novel vaccine delivery device developers. Each profile presents a brief overview of the company, its financial information (if available), information on its product portfolio, recent developments and an informed future outlook.

Chapter 9 features an elaborate analysis and discussion of the various collaborations and partnerships related to the novel vaccine delivery devices, which have been inked amongst players. It includes a brief description of the purpose of the partnership models (including R&D agreements, product development, licensing, distribution, research agreements, manufacturing agreements, acquisitions, product development and commercialization and others) that have been adopted by the stakeholders in this domain, since 2014. It consists of a schematic representation showcasing the players that have forged the maximum number of alliances. Furthermore, we have provided a world map representation of the deals inked in this field, highlighting those that have been established within and across different continents.

Chapter 10 provides a discussion on important industry-specific trends, key market drivers and challenges, under a SWOT framework, featuring a qualitative Harvey ball analysis, that highlights the relative impact of each SWOT parameter on the overall medical device label manufacturing industry.

Chapter 11 presents an insightful market forecast analysis, highlighting the future potential of novel vaccine delivery devices market, till the year 2030. We have segregated the opportunity of novel vaccine delivery devices on the basis of different types of device (electroporation-based needle free injection systems, oral delivery systems, nasal delivery systems, jet injectors, microneedle patches and microinjectors), route of administration (oral, intramuscular, intranasal, intradermal and subcutaneous, type of vaccine (Bivalent Oral Polio Vaccine, BCG Vaccine, DTP-HepB-Hib Vaccine, Pneumococcal Conjugate Vaccine, Influenza Vaccine, Measles Vaccine, Tetanus-Diphtheria Vaccine and Others) and key geographical regions (North America, Europe, Asia and rest of the world). 

Chapter 12 is a collection of interview transcripts of the discussions held with key stakeholders in this market. In this chapter, we have presented the details of interviews held with Michael Schrader (Chief Executive Officer and Founder, Vaxess Technologies), Mikael Ekstrom and Roger Lassing (Vice President, Business Development, Iconovo) and Henry King (Market Intelligence and Business Development Manager, Innoture).

Chapter 13 summarizes the entire report. It presents a list of key takeaways and offers our independent opinion on the current market scenario. Further, it captures the evolutionary trends that are likely to determine the future of this segment of the novel vaccine delivery devices industry.

Chapter 14 is an appendix, which provides tabulated data and numbers for all the figures included in the report.

Chapter 15 is an appendix, which contains a list of companies and organizations mentioned in this report.

Table Of Contents

1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION

3.1. An Overview of Vaccines
3.1.1. Classification of Vaccines
3.1.1.1. Live, Attenuated Vaccines
3.1.1.2. Inactivated Vaccines
3.1.1.3. Subunit Vaccines
3.1.1.4. Toxoid Vaccines
3.1.1.5. DNA Vaccines

3.1.2. Key Components of Vaccine Formulations
3.1.3. Production of Vaccines in Different Expression Systems
3.1.3.1. Embryonated Chicken Eggs and Primary Chicken Embryonic Fibroblasts (CEFs)
3.1.3.2. Mammalian Expression Systems
3.1.3.3. Avian Expression Systems
3.1.3.4. Plant Expression Systems
3.1.3.5. Bacterial Expression Systems
3.1.3.6. Yeast Expression Systems
3.1.3.7. Insect Expression System

3.1.4. Routes of Administration for Vaccines
3.1.4.1. Intradermal Route
3.1.4.2. Subcutaneous Route
3.1.4.3. Intramuscular Route
3.1.4.4. Oral Route
3.1.4.5. Intranasal Route
3.1.4.6. Inhalation

3.1.5. Key Challenges Associated with Vaccine Delivery
3.1.6. Novel Approaches for Vaccine Delivery Devices
3.1.6.1. Autoinjectors
3.1.6.2. Biodegradable Implants
3.1.6.3. Buccal / Sublingual Vaccine Delivery Systems
3.1.6.4. Electroporation
3.1.6.5. Inhalation / Pulmonary Vaccine Delivery Systems
3.1.6.6. Jet Injectors
3.1.6.7. Microinjection System
3.1.6.8. Novel Oral Vaccine Formulations
3.1.7. Future Perspectives

4. MARKET LANDSCAPE
4.1. Chapter Overview
4.2. Marketed Vaccines Landscape
4.3. Clinical-Stage Vaccines Landscape

4.4. Novel Vaccine Delivery Devices: Overall Market Landscape
4.4.1. Analysis by Type of Device
4.4.2. Analysis by Route of Administration
4.4.3. Analysis by Drug Delivery Mechanism
4.4.4. Analysis by Nature of Vaccine Administration
4.4.5. Analysis by Speed of Vaccine Administration
4.4.6. Analysis by Self-Administration Potential
4.4.7. Analysis by Availability of Audio / Visual Feedback
4.4.8. Analysis by Device Usability
4.4.9. Analysis by Type of Needle
4.4.10. Analysis by Stage of Development

4.5. Novel Vaccine Delivery Device Developers: Overall Market Landscape
4.5.1. Analysis by Type of Developer
4.5.2. Analysis by Year of Establishment
4.5.3. Analysis by Company Size
4.5.4. Analysis by Geographical Location

5. DEVICE COMPETITIVENESS ANALYSIS
5.1. Chapter overview
5.2. Assumptions and Methodology
5.2.1. Device Competitiveness Analysis: Competitive Landscape

6. TECHNOLOGY EFFECTIVENESS ANALYSIS
6.1. Chapter Overview
6.2. Assumptions and Key Parameters
6.3. Methodology
6.4. Vaccine Delivery Devices: Technology Effectiveness Analysis
6.4.1. Devices for Marketed Vaccines
6.4.1.1. Analysis by Type of Active Ingredient
6.4.1.2. Analysis by Dosage Form
6.4.1.3. Analysis by Route of Administration
6.4.1.4. Analysis by Target Disease Indication
6.4.1.5. Analysis by Target Patient Population
6.4.2. Devices for Clinical-Stage Vaccines
6.4.2.1. Analysis by Type of Active Ingredient
6.4.2.2. Analysis by Dosage Form
6.4.2.3. Analysis by Route of Administration
6.4.2.4. Analysis by Target Disease Indication
6.4.2.5. Analysis by Target Patient Population

7. NOVEL VACCINE DELIVERY DEVICES: LIKELY VACCINE CANDIDATES
7.1. Chapter Overview
7.2. Methodology and Key Parameters

7.3. Marketed Vaccines
7.3.1. Electroporation-based Needle Free Injection Systems: Likely Vaccine 
7.3.1.1. Most Likely Candidates for Delivery via Electroporation-based Needle Free Injection Systems
7.3.1.2. Likely Candidates for Delivery via Electroporation-based Needle Free Injection SystemsSystems
7.3.1.3. Less Likely Candidates for Delivery via Electroporation-based Needle Free Injection Systems
7.3.1.4. Least Likely Candidates for Delivery via Electroporation-based Needle Free Injection Systems

7.3.2. Jet Injectors: Likely Vaccine Candidates
7.3.2.1. Most Likely Candidates for Delivery via Jet Injectors
7.3.2.2. Likely Candidates for Delivery via Jet Injectors
7.3.2.3. Less Likely Candidates for Delivery via Jet Injectors
7.3.2.4. Least Likely Candidates for Delivery via Jet Injector

7.3.3. Microneedle Patches: Likely Vaccine Candidates
7.3.3.1. Most Likely Candidates for Delivery via Microneedle Patches
7.3.3.2. Less Likely Candidates for Delivery via Microneedle Patches
7.3.3.3. Least Likely Candidates for Delivery via Microneedle Patches

7.3.4. Nasal delivery Systems: Likely Vaccine Candidates
7.3.4.1. Most Likely Candidates for Delivery via Nasal Delivery Systems
7.3.4.2. Likely Candidates for Delivery via Nasal Delivery Systems
7.3.4.3. Less Likely Candidates for Delivery via Nasal Delivery Systems
7.3.4.4. Least Likely Candidates for Delivery via Nasal Delivery Systems

7.3.5. Oral Delivery Systems for Liquid Formulations: Likely Vaccine Candidates
7.3.5.1. Most Likely Candidates for Delivery via Oral Delivery Systems for Liquid Formulations
7.3.5.2. Likely Candidates for Delivery via Oral Delivery Systems for Liquid Formulations
7.3.5.3. Less Likely Candidates for Delivery via Oral Delivery Systems for Liquid Formulations
7.3.5.4. Least Likely Candidates for Delivery via Oral Delivery Systems for Liquid Formulations
 
7.3.6. Oral Delivery Systems for Solid Formulations: Likely Vaccine Candidates
7.3.6.1. Most Likely Candidates for Delivery via Oral Delivery Systems for Solid Formulations
7.3.6.2. Likely Candidates for Delivery via Oral Delivery Systems for Solid Formulations
7.3.6.3. Less Likely Candidates for Delivery via Oral Delivery Systems for Solid Formulations
7.3.6.4. Least Likely Candidates for Delivery via Oral Delivery Systems for Solid Formulations

7.3.7. Prefilled Syringes: Likely Vaccine Candidates
7.3.7.1. Most Likely Candidates for Delivery via Prefilled Syringes
7.3.7.2. Likely Candidates for Delivery via Prefilled Syringes
7.3.7.3. Less Likely Candidates for Delivery via Prefilled Syringes
7.3.7.4. Least Likely Candidates for Delivery via Prefilled Syringes

7.4. Clinical-Stage Vaccines
7.4.1. Electroporation-based Needle Free Injection Systems: Likely Vaccine Candidates
7.4.1.1. Most Likely Candidates for Delivery via Electroporation-based Needle Free Injection Systems
7.4.1.2. Likely Candidates for Delivery via Electroporation-based Needle Free Injection Systems
7.4.1.3. Less Likely Candidates for Delivery via Electroporation-based Needle Free Injection Systems
7.4.1.4. Least Likely Candidates for Delivery via Electroporation-based Needle Free Injection Systems

7.4.2. Jet Injectors: Likely Vaccine Candidates
7.4.2.1. Most Likely Candidates for Delivery via Jet Injectors
7.4.2.2. Likely Candidates for Delivery via Jet Injectors
7.4.2.3. Less Likely Candidates for Delivery via Jet Injectors
7.4.2.4. Least Likely Candidates for Delivery via Jet Injectors

7.4.3. Microneedle Patches: Likely Vaccine Candidates
7.4.3.1. Most Likely Candidates for Delivery via Microneedle Patches
7.4.3.2. Likely Candidates for Delivery via Microneedle Patches
7.4.3.3. Less Likely Candidates for Delivery via Microneedle Patches
7.4.3.4. Least Likely Candidates for Delivery via Microneedle Patches

7.4.4. Nasal Delivery Systems: Likely Vaccine Candidates
7.4.4.1. Most Likely Candidates for Delivery via Nasal Delivery Systems
7.4.4.2. Likely Candidates for Delivery via Nasal Delivery Systems
7.4.4.3. Less Likely Candidates for Delivery via Nasal Delivery Systems
7.4.4.4. Least Likely Candidates for Delivery via Nasal Delivery Systems

7.4.5. Oral Delivery Systems for Liquid Formulations: Likely Vaccine Candidates
7.4.5.1. Most Likely Candidates for Delivery via Oral Delivery Systems for Liquid Formulations
7.4.5.2. Likely Candidates for Delivery via Oral Delivery Systems for Liquid Formulations
7.4.5.3. Less Likely Candidates for Delivery via Oral Delivery Systems for Liquid Formulations
7.4.5.4. Least Likely Candidates for Delivery via Oral Delivery Systems for Liquid Formulations

7.4.6. Oral Delivery Systems for Solid Formulations: Likely Vaccine Candidates
7.4.6.1. Most Likely Candidates for Delivery via Oral Delivery Systems for Solid Formulations
7.4.6.2. Likely Candidates for Delivery via Oral Delivery Systems for Solid Formulations
7.4.6.3. Less Likely Candidates for Delivery via Oral Delivery Systems for Solid Formulations
7.4.6.4. Least Likely Candidates for Delivery via Oral Delivery Systems for Solid Formulations

7.4.7. Prefilled Syringes: Likely Vaccine Candidates
7.4.7.1. Most Likely Candidates for Delivery via Prefilled Syringes
7.4.7.2. Likely Candidates for Delivery via Prefilled Syringes
7.4.7.3. Less Likely Candidates for Delivery via Prefilled Syringes
7.4.7.4. Least Likely Candidates for Delivery via Prefilled Syringes

8. COMPANY PROFILES
8.1. Company Overview
8.2. 3M
8.2.1. Company Overview
8.2.2. Financial Information
8.2.3. Product Portfolio
8.2.3.1. 3M™ Hollow Microstructured Transdermal System
8.2.3.2. 3M™ Solid Microneedle
8.2.4. Recent Collaborations
8.2.5. Future Outlook

8.3. Becton Dickinson
8.3.1. Company Overview
8.3.2. Financial Information
8.3.3. Product Portfolio
8.3.3.1. BD Intevia™ Handheld Autoinjector
8.3.3.2. BD Accuspray™ Nasal Spray System
8.3.4. Future Outlook

8.4. Consort Medical
8.4.1. Company overview
8.4.2. Financial Information
8.4.3. Technology Overview
8.4.4. Product Portfolio
8.4.4.1. Autoinjectors
8.4.4.1.1. Syrina
8.4.4.1.2. OTS Autoinjector
8.4.4.2. Nasal Delivery System
8.4.5. Recent Collaborations
8.4.6. Future Outlook

8.5. D'Antonio Consultants International
8.5.1. Company Overview
8.5.2. Product Portfolio
8.5.2.1. LectraJet® High Speed Jet Injection System
8.5.2.2. LectraJet® M3 RA Needle-Free Injection System
8.5.2.3. LectraJet® M4 RA Needle-Free Injection System
8.5.2.4. Multi-Channel Jet Injector

8.6. Enesi Pharma
8.6.1. Company Overview
8.6.2. Product Portfolio
8.6.2.1. Enesi ImplaVax®
8.6.3. Recent Collaborations
8.6.4. Future Outlook

8.7. Ichor Medical Systems
8.7.1. Company Overview
8.7.2. Product Portfolio
8.7.2.1. TriGrid® Delivery System
8.7.3. Recent Collaborations
8.7.4. Future Outlook

8.8. Iconovo
8.8.1. Company Overview
8.8.2. Financial Information
8.8.3. Product Portfolio
8.8.3.1. ICOres
8.8.3.2. ICOone
8.8.3.3. ICocap
8.8.3.4. ICopre
8.8.4. Recent Collaborations
8.8.5. Future Outlook

8.9. Inovio Pharmaceuticals
8.9.1. Company Overview
8.9.2. Financial Information
8.9.3. Product Portfolio
8.9.3.1. ZetaJet®
8.9.3.2. Biojector® 2000
8.9.3.3. CELLECTRA® Electroporation Delivery Device
8.9.4. Recent Collaborations
8.9.5. Future Outlook

8.10. PharmaJet
8.10.1. Company Profile
8.10.2. Product Portfolio
8.10.2.1. PharmaJet Stratis® Needle-Free Injector
8.10.2.2. PharmaJet Tropis® Intradermal Injection
8.10.3. Recent Collaborations
8.10.4. Future Outlook

8.11. Union Medico
8.11.1. Company Overview
8.11.2. Product Portfolio
8.11.2.1. 45˚ Autoinjector
8.11.2.1.1. 45 ˚/ S Autoinjector
8.11.2.1.2. 45 ˚/ M Autoinjector
8.11.2.1.3. 45 ˚/ R Autoinjector

8.11.2.2. 90˚Autoinjector
8.11.2.2.1. 90 ˚ / S Autoinjector
8.11.2.2.2. 90 ˚ / M Autoinjector
8.11.2.2.3. 90 ˚ / XL Autoinjector
8.11.2.2.4. SuperGrip Autoinjector
8.11.2.2.5. Exclusive Autoinjector
8.11.3. Recent Development and Future Outlook

9. PARTNERSHIPS AND COLLABORATIONS
9.1. Chapter Overview
9.2. Partnership Models
9.3. Novel Vaccine Delivery Devices: Partnerships and Collaborations
9.3.1. Analysis by Year of Partnership
9.3.2. Analysis by Type of Partnership
9.3.3. Analysis by Type of Device
9.3.4. Analysis by Type of Partnership and Type of Device
9.3.5. Analysis by Type of Vaccine and Type of Device
9.3.6. Analysis by Type of Active Ingredient
9.3.7. Analysis by Target Disease Indication
9.3.8. Popular Vaccine Delivery Devices: Analysis by Number of Partnerships
9.3.9. Most Active Industry Players: Analysis by Number of Partnerships
9.3.10. Intercontinental and Intracontinental Agreements

10. SWOT ANALYSIS
10.1. Chapter Overview
10.2. Strengths
10.2.1. Minimally Invasive / Non-Invasive Vaccine Delivery
10.2.2. Ease of Use
10.2.3. Elimination of Cold-Chain Storage
10.2.4. Economic Advantages
10.2.5. Elimination of Medication Errors

10.3. Weaknesses
10.3.1. Manufacturing Complexities
10.3.2. Cost Concerns
10.3.3. Product Stability Concerns

10.4. Opportunities
10.4.1. Growing Pipeline of Vaccines
10.4.2. Increase in Self-Injecting Patient Population
10.4.3. Growing Incidence of Infectious Diseases
10.4.4. Innovation in Design and Technical Advancements
10.4.5. Geographic Expansions

10.5. Threats
10.5.1. Competition from Conventional Delivery Systems
10.5.2. Strict Regulatory Framework

10.6. Concluding Remarks

11. MARKET SIZING AND OPPORTUNITY ANALYSIS
11.1. Chapter Overview
11.2. Forecast Methodology and Key Assumptions
11.3. Global Novel Vaccine Delivery Device Market, 2019-2030
11.3.1. Global Novel Vaccine Delivery Device Market, 2019-2030 (By Value)
11.3.1.1. Global Novel Vaccine Delivery Devices Market: Distribution by Type of Device, 2019-2030 (By Value)
11.3.1.2. Global Novel Vaccine Delivery Device Market: Distribution by Route of Administration 2019-2030 (By Value)
11.3.1.3. Global Novel Vaccine Delivery Device Market: Distribution by Type of Vaccine 2019-2030 (By Value)
11.3.1.4. Global Novel Vaccine Delivery Device Market: Distribution by Regions, 2019-2030 (By Value)
11.3.1.4.1. Novel Vaccine Delivery Devices Market in North America, 2019-2030 (By Value)
11.3.1.4.1.1. Novel Vaccine Delivery Devices Market in North America: Distribution by Type of Device, 2019-2030 (By Value)
11.3.1.4.1.2. Novel Vaccine Delivery Devices Market in North America: Distribution by Route of Administration, 2019-2030 (By Value)
11.3.1.4.1.3. Novel Vaccine Delivery Devices Market in North America: Distribution by Type of Vaccine, 2019-2030 (By Value)

11.3.1.4.2. Novel Vaccine Delivery Devices Market in Europe, 2019-2030 (By Value)
11.3.1.4.2.1. Novel Vaccine Delivery Devices Market in Europe: Distribution by Type of Device, 2019-2030 (By Value)
11.3.1.4.2.2. Novel Vaccine Delivery Devices Market in Europe: Distribution by Route of Administration, 2019-2030 (By Value)
11.3.1.4.2.3. Novel Vaccine Delivery Devices Market in Europe: Distribution by Type of Vaccine, 2019-2030 (By Value)

11.3.1.4.3. Novel Vaccine Delivery Devices Market in Asia Pacific, 2019-2030 (By Value)
11.3.1.4.3.1. Novel Vaccine Delivery Devices Market in Asia Pacific: Distribution by Type of Device, 2019-2030 (By Value)
11.3.1.4.3.2. Novel Vaccine Delivery Devices Market in Asia Pacific: Distribution by Route of Administration, 2019-2030 (By Value)
11.3.1.4.3.3. Novel Vaccine Delivery Devices Market in Asia Pacific: Distribution by Type of Vaccine, 2019-2030 (By Value)

11.3.1.4.4. Novel Vaccine Delivery Devices Market in Rest of the World, 2019-2030 (By Value)
11.3.1.4.4.1. Novel Vaccine Delivery Devices Market in Rest of the World: Distribution by Type of Device, 2019-2030 (By Value)
11.3.1.4.4.2. Novel Vaccine Delivery Devices Market in Rest of the World: Distribution by Route of Administration, 2019-2030 (By Value)
11.3.1.4.4.3. Novel Vaccine Delivery Devices Market in Rest of the World: Distribution by Type of Vaccine, 2019-2030 (By Value)

11.3.2. Global Novel Vaccine Delivery Device Market, 2019-2030 (By Volume)
11.3.2.1. Global Novel Vaccine Delivery Device Market: Distribution by Type of Device, 2019-2030 (By Volume)
11.3.2.2. Global Novel Vaccine Delivery Device Market: Distribution by Route of Administration, 2019-2030 (By Volume)
11.3.2.3. Global Novel Vaccine Delivery Device Market: Distribution by Type of Vaccine, 2019-2030 (By Volume)
11.3.2.4. Global Novel Vaccine Delivery Device Market: Distribution by Regions, 2019-2030 (By Volume)

11.3.2.4.1. Novel Vaccine Delivery Device Market in North America, 2019-2030 (By Volume)
11.3.2.4.1.1. Novel Vaccine Delivery Devices Market in North America: Distribution by Type of Device, 2019-2030 (By Volume)
11.3.2.4.1.2. Novel Vaccine Delivery Devices Market in North America: Distribution by Route of Administration, 2019-2030 (By Volume)
11.3.2.4.1.3. Novel Vaccine Delivery Devices Market in North America: Distribution by Type of Vaccine, 2019-2030 (By Volume)

11.3.2.4.2. Novel Vaccine Delivery Devices Market in Europe, 2019-2030 (By Volume)
11.3.2.4.2.1. Novel Vaccine Delivery Devices Market in Europe: Distribution by Type of Device, 2019-2030 (By Volume)
11.3.2.4.2.2. Novel Vaccine Delivery Devices Market in Europe: Distribution by Route of Administration, 2019-2030 (By Volume)
11.3.2.4.2.3. Novel Vaccine Delivery Devices Market in Europe: Distribution by Type of Vaccine, 2019-2030 (By Volume)

11.3.2.4.3. Novel Vaccine Delivery Devices Market in Asia Pacific, 2019-2030 (By Volume)
11.3.2.4.3.1. Novel Vaccine Delivery Devices Market in Asia Pacific: Distribution by Type of Device, 2019-2030 (By Volume)
11.3.2.4.3.2. Novel Vaccine Delivery Devices Market in Asia Pacific: Distribution by Route of Administration, 2019-2030 (By Volume)
11.3.2.4.3.3. Novel Vaccine Delivery Devices Market in Asia Pacific: Distribution by Type of Vaccine, 2019-2030 (By Volume)

11.3.2.4.4. Novel Vaccine Delivery Devices Market in Rest of the World, 2019-2030 (By Volume)
11.3.2.4.4.1. Novel Vaccine Delivery Devices Market in Rest of the World: Distribution by Type of Device, 2019-2030 (By Volume)
11.3.2.4.4.2. Novel Vaccine Delivery Devices Market in Rest of the World: Distribution by Route of Administration, 2019-2030 (By Volume)
11.3.2.4.4.3. Novel Vaccine Delivery Devices Market in Rest of the World: Distribution by Type of Vaccine, 2019-2030 (By Volume)

12. EXECUTIVE INSIGHTS
12.1. Chapter Overview
12.2. Vaxess Technologies
12.2.1. Company Snapshot
12.2.1.1. Interview Transcript: Michael Schrader, Chief Executive Officer and Founder

12.3. Iconovo
12.3.1. Company Snapshot
12.3.1.1. Interview Transcript: Mikael Ekstrom and Roger Lassing, Vice Presidents, Business Development

12.4. Innoture
12.4.1. Company Snapshot
12.4.1.1. Interview Transcript: Henry King, Market Intelligence and Development Manager

13. CONCLUDING REMARKS
13.1. Chapter Overview
13.2. Key Takeaways

14. APPENDIX I: TABULATED DATA

15. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

List Of Figuers

Figure 3.1  Difference Between Vaccines and Small Molecule
Figure 3.2  Classification of Vaccines
Figure 3.3  Routes for Vaccine Administration
Figure 3.4  Routes of Administration for Vaccines
Figure 3.5  Novel Vaccine Delivery Devices
Figure 4.1  Novel Vaccine Delivery Devices: Distribution by Type of Device
Figure 4.2  Novel Vaccine Delivery Devices: Distribution by Route of Administration  
Figure 4.3  Novel Vaccine Delivery Devices: Distribution by Type of Device and Route of Administration
Figure 4.4  Novel Vaccine Delivery Devices: Distribution by Drug Delivery Mechanism
Figure 4.5  Novel Vaccine Delivery Devices: Distribution by Type of Device and Drug Delivery Mechanism
Figure 4.6  Novel Vaccine Delivery Devices: Distribution by Nature of Vaccine Administration
Figure 4.7  Novel Vaccine Delivery Devices: Analysis by Type of Device and Nature of Vaccine Administration
Figure 4.8  Novel Vaccine Delivery Devices: Distribution by Speed of Vaccine Administration
Figure 4.9  Novel Vaccine Delivery Devices: Distribution by Type of Device and Speed of Vaccine Administration
Figure 4.10  Novel Vaccine Delivery Devices: Distribution by Self-Administration Potential
Figure 4.11  Novel Vaccine Delivery Devices: Distribution by Type of Device and Self-Administration Potential
Figure 4.12  Novel Vaccine Delivery Devices: Analysis by Availability of Audio / Visual Feedback
Figure 4.13  Novel Vaccine Delivery Devices: Analysis by Type of Device and Availability of Audio / Visual Feedback
Figure 4.14  Novel Vaccine Delivery Devices: Distribution by Device Usability
Figure 4.15  Novel Vaccine Delivery Devices: Distribution by Type of Device and Device Usability
Figure 4.16  Novel Vaccine Delivery Devices: Distribution by Type of Needle
Figure 4.17  Novel Vaccine Delivery Devices: Analysis by Type of Device and Type of Needle
Figure 4.18  Novel Vaccine Delivery Devices: Distribution by Stage of Development
Figure 4.19  Novel Vaccine Delivery Devices: Distribution by Type of Device and Stage of Development
Figure 4.20  Novel Vaccine Delivery Device Developers: Distribution by Type of Developer
Figure 4.21  Novel Vaccine Delivery Device Developers: Distribution by Year of Establishment
Figure 4.22  Novel Vaccine Delivery Device Developers: Distribution by Company Size
Figure 4.23  Novel Vaccine Delivery Device Developers: Distribution by Geographical Location
Figure 5.1  Novel Vaccine Delivery Devices: Dot Plot Analysis
Figure 5.2  Device Competitiveness Analysis: Novel vaccine Delivery Devices
Figure 6.1  Technology Effectiveness: Analysis by Type of Active Ingredient
Figure 6.2  Technology Effectiveness: Analysis by Route of Administration
Figure 6.3  Technology Effectiveness: Analysis by Target Patient Population
Figure 6.4  Technology Effectiveness: Analysis by Type of Active Ingredient
Figure 6.5  Technology Effectiveness: Analysis by Route of Administration
Figure 6.6  Technology Effectiveness: Analysis by Target Patient Population
Figure 8.1  3M: Annual Revenues, 2015-Q3 2019 (USD Billion)
Figure 8.2  3M™ Hollow Microstructured Transdermal System: Approval Process
Figure 8.3  3M™ Hollow Microstructured Transdermal System: Advantages
Figure 8.4  Solid Microneedle: Advantages
Figure 8.5  Becton Dickinson: Annual Revenues, 2014-Q3 2019 (USD Billion)
Figure 8.6  Consort Medical: Annual Revenues, 2015-2019 (GBP Million)
Figure 8.7  Consort Medical: Syrina® Autoinjectors
Figure 8.8  LectraJet® HS High Speed Jet Injection: Features
Figure 8.9  ImplaVax®: Components
Figure 8.10  ImplaVax®: Features
Figure 8.11 Ichor Medical Systems: Electroporation-based Vaccine Delivery
Figure 8.12  Iconovo: Dry Powder Inhalers
Figure 8.13  Inovio Pharmaceutical: Annual Revenues, 2014-Q3, 2019 (USD Million)
Figure 8.14  PhrmaJet Tropis Intradermal Injection: Administration Steps
Figure 8.15  Union Medico: Types of 45˚Autoinjector
Figure 8.16  Union Medico: Components of 45˚/R Autoinjector
Figure 8.17  Union Medico: Types of 90˚ Autoinjectors
Figure 8.18  Union Medico: Components of Exclusive Autoinjector 
Figure 9.1  Partnerships and Collaborations: Distribution by Year, 2014-2019
Figure 9.2  Partnerships and Collaborations: Distribution by Type of Partnership
Figure 9.3  Partnerships and Collaborations: Distribution by Type of Device
Figure 9.4  Partnerships and Collaborations: Year-Wise Trend of Different Novel Type of Devices, 20014-2019
Figure 9.5  Partnerships and Collaborations: Distribution by Type of Partnership and Type of Device
Figure 9.6  Partnerships and Collaborations: Distribution by Type of Vaccine and Type of Device
Figure 9.7  Partnerships and Collaborations: Distribution by Type of Active Ingredient
Figure 9.8  Partnerships and Collaborations: Distribution by Target Disease Indication
Figure 9.9  Popular Vaccine Delivery Devices: Analysis by Number of Partnerships
Figure 9.10  Partnerships and Collaborations: Most Active Industry Players
Figure 9.11  Partnerships and Collaborations: Intercontinental and Intracontinental Distribution
Figure 10.1  Novel Vaccine Delivery Devices SWOT Analysis: Overview
Figure 10.2  Comparison of SWOT Factors: Harvey Ball Analysis
Figure 11.1  Novel Vaccine Delivery Devices Price Estimates (USD Per Unit)
Figure 11.2  Global Novel Vaccine Delivery Devices Market, 2019-2030 (USD Million)
Figure 11.3 Global Novel Vaccine Delivery Devices Market: Distribution by Type of Device, 2019-2030 (USD Million)
Figure 11.4 Global Novel Vaccine Delivery Devices Market: Distribution by Route of Administration, 2019-2030 (USD Million)
Figure 11.5 Global Novel Vaccine Delivery Devices: Distribution by Type of Vaccine, 2019-2030 (USD Million)
Figure 11.6  Global Novel Vaccine Delivery Devices: Distribution by Regions, 2019-2030 (USD Million)
Figure 11.7 Novel Vaccine Delivery Devices Market in North America, 2019-2030 (USD Million)
Figure 11.8 Novel Vaccine Delivery Devices Market in North America: Distribution by Type of Device, 2019-2030 (USD Million)
Figure 11.9  Novel Vaccine Delivery Devices Market in North America: Distribution by Route of Administration, 2019-2030 (USD Million)
Figure 11.10  Novel Vaccine Delivery Devices Market in North America: Distribution by Type of Vaccine, 2019-2030 (USD Million)
Figure 11.11  Novel Vaccine Delivery Devices Market in Europe, 2019-2030 (USD Million)
Figure 11.12  Novel Vaccine Delivery Devices Market in Europe: Distribution by Type of Device, 2019-2030 (USD Million)
Figure 11.13  Novel Vaccine Delivery Devices Market in Europe: Distribution by Route of Administration, 2019-2030 (USD Million)
Figure 11.14  Novel Vaccine Delivery Devices Market in Europe: Distribution by Type of Vaccine, 2019-2030 (USD Million)
Figure 11.15  Novel Vaccine Delivery Devices Market in Asia Pacific, 2019-2030 (USD Million)
Figure 11.16  Novel Vaccine Delivery Devices Market in Asia Pacific: Distribution by Type of Device, 2019-2030 (USD Million)
Figure 11.17  Novel Vaccine Delivery Devices Market in Asia Pacific: Distribution by Route of Administration, 2019-2030 (USD Million)
Figure 11.18  Novel Vaccine Delivery Devices Market in Asia Pacific: Distribution by Type of Vaccine, 2019-2030 (USD Million)
Figure 11.19  Novel Vaccine Delivery Devices Market in Rest of the World, 2019-2030 (USD Million)
Figure 11.20  Novel Vaccine Delivery Devices Market in Rest of the World: Distribution by Type of Device, 2019-2030 (USD Million)
Figure 11.21  Novel Vaccine Delivery Devices Market in Rest of the World: Distribution by Route of Administration, 2019-2030 (USD Million)
Figure 11.22  Novel Vaccine Delivery Devices Market in Rest of the World: Distribution by Type of Vaccine, 2019-2030 (USD Million)
Figure 11.23  Global Novel Vaccine Delivery Devices Market, 2019-2030 (Million Unit)
Figure 11.24  Global Novel Vaccine Delivery Devices Market, Distribution by Type of Device 2019-2030 (Million Unit)
Figure 11.25  Global Novel Vaccine Delivery Devices Market, Distribution by Type of Device, 2019-2030 (Million Unit)
Figure 11.26 Global Novel Vaccine Delivery Devices Market: Distribution by Route of Administration, 2019-2030 (Million Unit)
Figure 11.27  Global Novel Vaccine Delivery Devices Market: Distribution by Type of Vaccine, 2019-2030 (Million Unit)
Figure 11.28 Novel Vaccine Delivery Devices Market in North America, 2019-2030 (Million Unit)
Figure 11.29  Novel Vaccine Delivery Devices Market in North America: Distribution by Type of Device, 2019-2030 (Million Unit) 
Figure 11.30  Novel Vaccine Delivery Devices Market in North America: Distribution by Route of Administration, 2019-2030 (Million Unit)
Figure 11.31  Novel Vaccine Delivery Devices Market in North America: Distribution by Type of Vaccine, 2019-2030 (Million Unit)
Figure 11.32  Novel Vaccine Delivery Devices Market in Europe, 2019-2030 (Million Unit)
Figure 11.33  Novel Vaccine Delivery Devices Market in Europe: Distribution by Type of Device, 2019-2030 (Million Unit)
Figure 11.34 Novel Vaccine Delivery Devices Market in Europe: Distribution by Route of Administration, 2019-2030 (Million Unit)
Figure 11.35  Novel Vaccine Delivery Devices Market in Europe: Distribution by Type of Vaccine, 2019-2030 (Million Unit)
Figure 11.36  Novel Vaccine Delivery Devices Market in Asia Pacific, 2019-2030 (Million Unit)
Figure 11.37  Novel Vaccine Delivery Devices Market in Asia Pacific: Distribution by Type of Device, 2019-2030 (Million Unit)
Figure 11.38  Novel Vaccine Delivery Devices Market in Asia Pacific: Distribution by Route of Administration, 2019-2030 (Million Unit)
Figure 11.39  Novel Vaccine Delivery Devices Market in Asia Pacific: Distribution by Type of Vaccine, 2019-2030 (Million Unit)
Figure 11.40  Novel Vaccine Delivery Devices Market in Rest of the World, 2019-2030 (Million Unit)
Figure 11.41  Novel Vaccine Delivery Devices Market in Rest of the World: Distribution by Type of Device, 2019-2030 (Million Unit)
Figure 11.42  Novel Vaccine Delivery Devices Market in Rest of the World: Distribution by Route of Administration, 2019-2030 (Million Unit)
Figure 11.43  Novel Vaccine Delivery Devices Market in Rest of the World: Distribution by Type of Vaccine, 2019-2030 (Million Unit)

List Of Tables

Table 3.1  Vaccines: Classification based on Method of Development
Table 3.2  Live Attenuated Vaccines: Commonly Reported Adverse Events
Table 3.3  Inactivated Vaccines: Commonly Reported Adverse Events
Table 3.4  Subunit Vaccines: Commonly Reported Adverse Events
Table 3.5  Toxoid Vaccines: Commonly Reported Adverse Events
Table 3.6  Vaccine Excipients and their Functions
Table 3.7  Vaccine Administration Routes and Type of Delivery Devices used
Table 3.8  Common Pediatric Vaccines and their Routes of Administration
Table 4.1  List of Marketed Vaccines, 
Table 4.2  List of Clinical-Stage Vaccines, 
Table 4.3  Novel Vaccine Delivery Devices: List of Available / Under Development Products
Table 4.4  Novel Vaccine Delivery Devices: Distribution of Developers
Table 6.1  Technology Effectiveness: Analysis by Dosage Form
Table 6.2  Technology Effectiveness: Analysis by Target Disease Indication
Table 6.3  Technology Effectiveness: Analysis by Dosage Form
Table 6.4  Technology Effectiveness: Analysis by Target Disease Indication
Table 7.1  Marketed Vaccines: Likely Candidates for Delivery via Novel Vaccine Delivery Devices
Table 7.2  Marketed Vaccines: Most Likely Candidates for Delivery via Electroporation-based Needle Free Injection Systems
Table 7.3 Marketed Vaccines: Likely Candidates for Delivery via Electroporation-based Needle Free Injection Systems
Table 7.4  Marketed Vaccines: Less Likely Candidates for Delivery via Electroporation-based Needle Free Injection Systems
Table 7.5  Marketed Vaccines: Least Likely Candidates for Delivery via Electroporation-based Needle Free Injection Systems
Table 7.6  Marketed Vaccines: Most Likely Candidates for Delivery via Jet Injectors
Table 7.7  Marketed Vaccines: Likely Candidates for Delivery via Jet Injectors
Table 7.8  Marketed Vaccines: Less Likely Candidates for Delivery via Jet Injectors
Table 7.9 Marketed Vaccines: Least Likely Candidates for Delivery via Jet Injectors
Table 7.10  Marketed Vaccines: Most Likely Candidates for Delivery via Microneedle Patches
Table 7.11  Marketed Vaccines: Less Likely Candidates for Delivery via Microneedle Patches
Table 7.12  Marketed Vaccines: Least Likely Candidates for Delivery via Microneedle Patches
Table 7.13  Marketed Vaccines: Most Likely Candidates for Delivery via Nasal Delivery Systems
Table 7.14  Marketed Vaccines: Likely Candidates for Delivery via Nasal Delivery Systems
Table 7.15  Marketed Vaccines: Less Likely Candidates for Delivery via Nasal Delivery Systems
Table 7.16  Marketed Vaccines: Least Likely Candidates for Delivery via Nasal Delivery Systems
Table 7.17  Marketed Vaccines: Most Likely Candidates for Delivery via Oral Delivery Systems for Liquid Formulations
Table 7.18  Marketed Vaccines: Likely Candidates for Delivery via Oral Delivery Systems for        Liquid Formulations
Table 7.19  Marketed Vaccines: Less Likely Candidates for Delivery via Oral Delivery Systems for Liquid Formulations
Table 7.20 Marketed Vaccines: Least Likely Candidates for Delivery via Oral Delivery Systems for Liquid Formulations
Table 7.21  Marketed Vaccines: Most Likely Candidates for Delivery via Oral Delivery Systems for Solid Formulations
Table 7.22  Marketed Vaccines: Likely Candidates for Delivery via Oral Delivery Systems for Solid Formulations
Table 7.23  Marketed Vaccines: Less Likely Candidates for Delivery via Oral Delivery Systems for Solid Formulations
Table 7.24  Marketed Vaccines: Least Likely Candidates for Delivery via Oral Delivery Systems for Solid Formulations
Table 7.25  Marketed Vaccines: Most Likely Candidates for Delivery via Prefilled Syringes
Table 7.26  Marketed Vaccines: Likely Candidates for Delivery via Prefilled Syringes
Table 7.27  Marketed Vaccines: Less Likely Candidates for Delivery via Prefilled Syringes
Table 7.28  Marketed Vaccines: Least Likely Candidates for Delivery via Prefilled Syringes
Table 7.29  Clinical-Stage Vaccines: Likely Candidates for Delivery Via Novel Vaccine Delivery Devices
Table 7.30  Clinical-Stage Vaccines: Most Likely Candidates for Delivery via Electroporation-based Needle Free Injection Systems
Table 7.31  Clinical-Stage Vaccines: Likely Candidates for Delivery via Electroporation-based Needle Free Injection Systems
Table 7.32  Clinical-Stage Vaccines: Less Likely Candidates for Delivery via Electroporation-based Needle Free Injection Systems
Table 7.33  Clinical-Stage Vaccines: Least Likely Candidates for Delivery via Electroporation-based Needle Free Injection Systems\
Table 7.34  Clinical-Stage Vaccines: Most Likely Candidates for Delivery via Jet Injectors
Table 7.35  Clinical-Stage Vaccines: Likely Candidates for Delivery via Jet Injectors
Table 7.36  Clinical-Stage Vaccines: Less Likely Candidates for Delivery via Jet Injectors
Table 7.37  Clinical-Stage Vaccines: Least Likely Candidates for Delivery via Jet Injectors
Table 7.38  Clinical- Stage Vaccines: Most Likely Candidates for Delivery via Microneedle Patches
Table 7.39  Clinical-Stage Vaccines: Likely Candidates for Delivery via Microneedle Patches
Table 7.40  Clinical-Stage Vaccines: Less Likely Candidates for Delivery via Microneedle Patches
Table 7.41  Clinical-Stage Vaccines: Least Likely Candidates for Delivery via Microneedle Patches
Table 7.42 Clinical Vaccines: Most Likely Candidates for Delivery via Nasal Delivery Systems
Table 7.43  Clinical Vaccines: Likely Candidates for Delivery via Nasal Delivery Systems
Table 7.44  Clinical-Stage Vaccines: Less Likely Candidates for Delivery via Nasal Delivery Systems
Table 7.45  Clinical-Stage Vaccines: Least Likely Candidates for Delivery via Nasal Delivery Systems
Table 7.46  Clinical-Stage Vaccines: Most Likely Candidates for Delivery via Oral Delivery Systems for Liquid Formulations
Table 7.47  Clinical-Stage Vaccines: Likely Candidates for Delivery via Oral Delivery Systems for Liquid Formulations
Table 7.48  Clinical-Stage Vaccines: Less Likely Candidates for Delivery via Oral Delivery Systems for Liquid Formulations
Table 7.49  Clinical-Stage Vaccines: Least Likely Candidates for Delivery via Oral Delivery Systems for Liquid Formulations
Table 7.50  Clinical Vaccines: Most Likely Candidates for Delivery via Oral Delivery Systems for Solid Formulations
Table 7.51  Clinical-Stage Vaccines: Likely Candidates for Delivery via Oral Delivery Systems for Solid Formulations
Table 7.52  Clinical-Stage Vaccines: Less Likely Candidates for Delivery via Oral Delivery Systems for Solid Formulations
Table 7.53  Clinical-Stage Vaccines: Least Likely Candidates for Delivery via Oral Delivery Systems for Solid Formulations
Table 7.54  Clinical-Stage Vaccines: Most Likely Candidates for Delivery via Prefilled Syringes
Table 7.55  Clinical-Stage Vaccines: Likely Candidates for Delivery via Prefilled Syringes
Table 7.56  Clinical-Stage Vaccines: Less Likely Candidates for Delivery via Prefilled Syringes
Table 7.57  Clinical-Stage Vaccines: Least Likely Candidates for Delivery via Prefilled Syringes
Table 8.1  Novel Vaccine Delivery Devices: List of Companies Profiled
Table 8.2  3M: Recent Collaborations
Table 8.3  Becton Dickinson: Medical Devices Portfolio
Table 8.4  Becton Dickinson: Future Outlook
Table 8.5  Consort Medical: Recent Collaborations
Table 8.6  Consort Medical: Future Outlook
Table 8.7  D'Antonio Consultants International: Medical Devices Portfolio
Table 8.8  Enesi Pharma: Recent Collaborations
Table 8.9  Enesi Pharma: Future Outlook
Table 8.10  Ichor Medical Systems: Recent Collaborations
Table 8.11  Ichor Medical Systems: Future Outlook
Table 8.12  Iconovo: Recent Collaborations
Table 8.13  Iconovo: Future Outlook
Table 8.14  Inovio Pharmaceuticals: Recent Collaborations
Table 8.15  Inovio Pharmaceuticals: Future Outlook
Table 8.16  PharmaJet: Recent Collaborations
Table 8.17 PharmaJet: Future Outlook
Table 8.18  Union Medico: Comparison of 45˚ Autoinjectors
Table 8.19  Union Medico: Comparison of 90˚ Autoinjectors
Table 9.1  Novel Vaccine Delivery Devices: Partnerships and Collaborations, 2014-2019 (till September), 
Table 12.1  Vaxess Technologies: Company Snapshot
Table 12.2  Iconovo: Company Snapshot
Table 12.3  Innoture: Company Snapshot
Table 14.1  Novel Vaccine Delivery Devices: Distribution by Type of Device
Table 14.2  Novel Vaccine Delivery Devices: Distribution by Route of Administration
Table 14.3  Novel Vaccine Delivery Devices: Distribution by Type of Device and Route of Administration
Table 14.4  Novel Vaccine Delivery Devices: Distribution by Drug Delivery Mechanism
Table 14.5  Novel Vaccine Delivery Devices: Distribution by Type of Device and Drug Delivery Mechanism
Table 14.6  Novel Vaccine Delivery Devices: Distribution by Nature of Vaccine Administration
Table 14.7  Novel Vaccine Delivery Devices: Distribution by Type of Device and Nature of Vaccine Administration
Table 14.8  Novel Vaccine Delivery Devices: Distribution by Speed of Vaccine Administration
Table 14.9  Novel Vaccine Delivery Devices: Distribution by Type of Device and Speed of Vaccine Administration
Table14.10  Novel Vaccine Delivery Devices: Distribution by Self Administration Potential
Table 14.11  Novel Vaccine Delivery Devices: Distribution by Type of Device and Self Administration Potential
Table 14.12  Novel Vaccine Delivery Devices: Distribution by Availability of Audio / Visual Feedback
Table 14.13  Novel Vaccine Delivery Devices: Distribution by Type of Device and Availability of Audio / Visual Feedback
Table 14.14  Novel Vaccine Delivery Devices: Distribution by Device Usability
Table 14.15  Novel Vaccine Delivery Devices: Distribution by Type of Device and Device Usability
Table 14.16  Novel Vaccine Delivery Devices: Distribution by Type of Needle
Table 14.17  Novel Vaccine Delivery Devices: Distribution by Type of Device and Type of Needle
Table 14.18  Novel Vaccine Delivery Devices: Distribution by Stage of Development
Table 14.19  Novel Vaccine Delivery Devices: Distribution by Type of Device and Stage of Development
Table 14.20  Novel Vaccine Delivery Device Developers: Distribution by Type of Developer
Table 14.21  Novel Vaccine Delivery Devices Developers: Distribution by Year of Establishment
Table 14.22  Novel Vaccine Delivery Devices Developers: Distribution by Company Size
Table 14.23  Novel Vaccine Delivery Devices Developers: Distribution by Geographical Location
Table 14.24  Technology Effectiveness of Devices for Marketed Vaccines: Analysis by Type of Active Ingredient
Table 14.25  Technology Effectiveness of Devices for Marketed Vaccines: Analysis by Type by Route of Administration
Table 14.26  Technology Effectiveness of Devices for Marketed Vaccines: Analysis by Target Patient Population
Table 14.27  Technology Effectiveness of Devices for Clinical Vaccines: Analysis by Type of Active Ingredient
Table 14.28  Technology Effectiveness of Devices for Clinical Vaccines: Analysis by Rote of Administration
Table 14.29  Technology Effectiveness of Devices for Clinical Vaccines: Analysis by Route of Administration
Table 14.30  3M: Annual Revenues, 2015- Q3 2019 (USD Billion)
Table 14.31  Becton Dickinson: Annual Revenues, 2014- Q3 2019 (USD Billion)
Table 14.32  Consort Medical: Annual Revenues, 2015-2019 (GBP Billion)
Table 14.33  Inovio Pharmaceuticals: Annual Revenues, 2014- Q3 2019 (USD Billion)
Table 14.34  Partnership and Collaborations: Distribution by Year, 2014-2019
Table 14.35  Partnership and Collaborations: Distribution by Type of Partnership
Table 14.36  Partnership and Collaborations: Distribution by Type of Device
Table 14.37  Partnership and Collaborations: Distribution by Year and Type of Device
Table 14.38  Partnership and Collaborations: Distribution by Type of Active Ingredient
Table 14.39  Partnership and Collaborations: Distribution by Target Disease Indication
Table 14.40  Popular Vaccine Delivery Devices: Analysis by Number of Partnerships
Table 14.41  Partnership and Collaborations: Most Active Players
Table 14.42  Novel Vaccine Delivery Devices Price Estimates (USD Per Unit)
Table 14.43  Global Novel Vaccine Delivery Devices Market, 2019-2030, Conservative, Base and Optimistic Scenario (USD Million)
Table 14.44  Global Novel Vaccine Delivery Devices Market: Distribution by Type of Device, 2019-2030, Conservative, Base and Optimistic Scenario (USD Million)
Table 14.45  Global Novel Vaccine Delivery Devices Market: Distribution by Route of Administration, 2019-2030, Conservative, Base and Optimistic Scenario (USD Million)
Table 14.46  Global Novel Vaccine Delivery Devices Market: Distribution by Type of Vaccine, 2019-2030, Conservative, Base and Optimistic Scenario (USD Million)
Table 14.47  Global Novel Vaccine Delivery Devices Market: Distribution by Regions, 2019-2030, Conservative, Base and Optimistic Scenario (USD Million)
Table 14.48  Novel Vaccine Delivery Devices Market in North America, 2019-2030, Conservative, Base and Optimistic Scenario (USD Million)
Table 14.49  Novel Vaccine Delivery Devices Market in North America: Distribution by Type of Device, 2019-2030, Conservative, Base and Optimistic Scenario (USD Million)
Table 14.50  Novel Vaccine Delivery Devices Market in North America: Distribution by Route of Administration, 2019-2030, Conservative, Base and Optimistic Scenario (USD Million)
Table 14.51  Novel Vaccine Delivery Devices Market in North America: Distribution by Type of Vaccine, 2019-2030 (USD Million)
Table 14.52  Novel Vaccine Delivery Devices Market in Europe, 2019-2030, Conservative, Base and Optimistic Scenario (USD Million)
Table 14.53  Novel Vaccine Delivery Devices Market in Europe: Distribution by Type of Device, 2019-2030, Conservative, Base and Optimistic Scenario (USD Million)
Table 14.54  Novel Vaccine Delivery Devices Market in Europe: Distribution by Route of Administration, 2019-2030, Conservative, Base and Optimistic Scenario (USD Million)
Table 14.55  Novel Vaccine Delivery Devices Market in Europe: Distribution by Type of Vaccine, 2019-2030, Conservative, Base and Optimistic Scenario (USD Million)
Table 14.56  Novel Vaccine Delivery Devices Market in Asia Pacific, 2019-2030, Conservative, Base and Optimistic Scenario (USD Million)
Table 14.57  Novel Vaccine Delivery Devices Market in Asia Pacific: Distribution by Type of Device, 2019-2030, Conservative, Base and Optimistic Scenario (USD Million)
Table 14.58  Novel Vaccine Delivery Devices Market in Asia Pacific: Distribution by Route of Administration, 2019-2030, Conservative, Base and Optimistic Scenario (USD Million)
Table 14.59  Novel Vaccine Delivery Devices Market in Asia Pacific: Distribution by Type of Vaccine, 2019-2030, Conservative, Base and Optimistic Scenario (USD Million)
Table 14.60  Novel Vaccine Delivery Devices Market in Rest of the World, 2019-2030, Conservative, Base and Optimistic Scenario (USD Million)
Table 14.61  Novel Vaccine Delivery Devices Market in Rest of the World: Distribution by Type of Device, 2019-2030, Conservative, Base and Optimistic Scenario (USD Million)
Table 14.62  Novel Vaccine Delivery Devices Market in Rest of the World: Distribution by Route of Administration, 2019-2030, Conservative, Base and Optimistic Scenario (USD Million)
Table 14.63  Novel Vaccine Delivery Devices Market in Rest of the World: Distribution by Type of Vaccine, 2019-2030, Conservative, Base and Optimistic Scenario (USD Million)
Table 14.64  Global Novel Vaccine Delivery Devices Market, 2019-2030, Conservative, Base and Optimistic Scenario (Million Unit)
Table 14.65  Global Novel Vaccine Delivery Devices Market: Distribution by Type of Device, 2019-2030, Conservative, Base and Optimistic Scenario (Million Unit)
Table 14.66  Global Novel Vaccine Delivery Devices Market: Distribution by Route of Administration, 2019-2030, Conservative, Base and Optimistic Scenario (Million Unit)
Table 14.67  Global Novel Vaccine Delivery Devices Market: Distribution by Type of Vaccine, 2019-2030, Conservative, Base and Optimistic Scenario (Million Unit)
Table 14.68  Global Novel Vaccine Delivery Devices Market: Distribution by Regions, 2019-2030 Conservative, Base and Optimistic Scenario (Million Unit)
Table 14.69  Novel Vaccine Delivery Devices Market in North America, 2019-2030, Conservative, Base and Optimistic Scenario (Million Unit)
Table 14.70  Novel Vaccine Delivery Devices Market in North America: Distribution by Type of Device, 2019-2030, Conservative, Base and Optimistic Scenario (Million Unit)
Table 14.71  Novel Vaccine Delivery Devices Market in North America: Distribution by Route of Administration, 2019-2030, Conservative, Base and Optimistic Scenario (Million Unit)
Table 14.72  Novel Vaccine Delivery Devices Market in North America: Distribution by Type of Vaccine, Conservative, Base and Optimistic Scenario 2019-2030 (Million Unit)
Table 14.73  Novel Vaccine Delivery Devices Market in Europe, 2019-2030, Conservative, Base and Optimistic Scenario (Million Unit)
Table 14.74  Novel Vaccine Delivery Devices Market in Europe: Distribution by Type of Device, 2019-2030, Conservative, Base and Optimistic Scenario (Million Unit)
Table 14.75  Novel Vaccine Delivery Devices Market in Europe: Distribution by Route of Administration, 2019-2030, Conservative, Base and Optimistic Scenario (Million Unit)
Table 14.76  Novel Vaccine Delivery Devices Market in Europe: Distribution by Type of Vaccine, 2019-2030, Conservative, Base and Optimistic Scenario (Million Unit)
Table 14.77  Novel Vaccine Delivery Devices Market in Asia Pacific, 2019-2030, Conservative, Base and Optimistic Scenario (Million Unit)
Table 14.78  Novel Vaccine Delivery Devices Market in Asia Pacific: Distribution by Type of Device, 2019-2030, Conservative, Base and Optimistic Scenario (Million Unit)
Table 14.79  Novel Vaccine Delivery Devices Market in Asia Pacific: Distribution by Route of Administration, 2019-2030, Conservative, Base and Optimistic Scenario (Million Unit)
Table 14.80  Novel Vaccine Delivery Devices Market in Asia Pacific: Distribution by Type of Vaccine, 2019-2030, Conservative, Base and Optimistic Scenario (Million Unit)
Table 14.81  Novel Vaccine Delivery Devices Market in Rest of the World, 2019-2030, Conservative, Base and Optimistic Scenario (Million Unit)
Table 14.82  Novel Vaccine Delivery Devices Market in Rest of the World: Distribution by Type of Device, 2019-2030, Conservative, Base and Optimistic Scenario (Million Unit)
Table 14.83  Novel Vaccine Delivery Devices Market in Rest of the World: Distribution by Route of Administration, 2019-2030, Conservative, Base and Optimistic Scenario (Million Unit)
Table 14.84  Novel Vaccine Delivery Devices Market in Rest of the World: Distribution by Type of Vaccine, 2019-2030, Conservative, Base and Optimistic Scenario (Million Unit)

Listed Companies

The following companies and organizations have been mentioned in the report:

  1. 3M
  2. Abbott 
  3. AbCellera
  4. ABO Pharmaceuticals
  5. AC Immune 
  6. Accelovance
  7. AdminMed 
  8. Aduro Biotech
  9. Advagene Biopharma
  10. Advaxis
  11. Aelix Therapeutics
  12. Aeras
  13. Aesica Pharmaceuticals
  14. Affinivax
  15. Affiris
  16. Agenus
  17. AgResearch 
  18. Aimmune Therapeutics
  19. Aivita Biomedical
  20. AJ Vaccines
  21. Aktiv-Dry 
  22. Alopexx Vaccine
  23. AlphaVax
  24. Altimmune
  25. American Association for Cancer Research
  26. Anhui Zhifei Longcom Biologic Pharmacy
  27. Animal Health Board
  28. Antares Pharma
  29. Apogee Technology
  30. Araclon Biotech 
  31. Archivel Farma
  32. Argos Therapeutics
  33. Astellas Pharma
  34. AstraZeneca
  35. Australian Respiratory and Sleep Medicine Institute
  36. AVIR Green Hills Biotechnology
  37. Axon Neuroscience
  38. Barr Labs
  39. Battelle
  40. Bavarian Nordic
  41. Baylor College of Medicine
  42. BCN Peptides
  43. Becton Dickinson
  44. Beijing Center for Disease Control and Prevention
  45. Beijing Institute of Biological Products
  46. Beijing Minhai Biotechnology
  47. Beijing Tricision Biotherapeutics
  48. Beijing Wantai Biological Pharmacy Enterprise
  49. Beijing Zhifei Lvzhu Biopharmaceutical
  50. Bernhard Nocht Institute for Tropical Medicine
  51. Bharat Biotech International
  52. Bill and Melinda Gates Foundation
  53. Bilthoven Biologicals
  54. Biofabri
  55. Bioject Medical Technologies
  56. Biological E
  57. Bio-Manguinhos
  58. Biomedical Advanced Research and Development Authority
  59. Biomedizinische Forschungs
  60. BioNTech
  61. BiondVax Pharmaceuticals
  62. Bioneedle Technologies Group
  63. Biontech
  64. BioSerenTach
  65. Birla Institute of Technology and Science
  66. Boehringer Ingelheim
  67. Boryung Pharmaceutical
  68. BrightPath Biotherapeutics
  69. Bristol-Myers Squibb
  70. Bul Bio-National Center of Infectious and Parasitic Diseases
  71. Cadila Health Care
  72. Cancer Insight
  73. Cancer Research UK
  74. Cancer Vaccines Charitable Trust
  75. CanSino Biologics
  76. Capital Medical University
  77. Celerion
  78. Celgene
  79. Celldex Therapeutics
  80. Centers for Disease Control and Prevention
  81. Center for Genetic Engineering and Biotechnology 
  82. Center for HIV/AIDS Vaccine Immunology (CHAVI)
  83. Changhai Hospital
  84. Charite University
  85. Chengdu Institute of Biological Products 
  86. Children's Hospital of Philadelphia
  87. Chinese PLA General Hospital
  88. Chiron Behring Vaccines
  89. Chumakov Federal Scientific Center for Research & Development of Immune-And Biological Products 
  90. City of Hope Medical Center
  91. College of Medicine and Allied Health Sciences
  92. Consort Medical
  93. Corium
  94. CosMED Pharmaceutical
  95. Cromos Pharma
  96. CSL
  97. CureVac
  98. Curevo
  99. DALI Medical Devices
  100. Dana-Farber Cancer Institute
  101. D'Antonio Consultants International
  102. Dartmouth-Hitchcock Medical Center
  103. Debiotech
  104. Department of Health and Human Services
  105. Duke University
  106. Dutch Cancer Society
  107. Dynavax Technologies
  108. E Ink Holdings
  109. E3D Elcam Drug Delivery Devices 
  110. Earle A. Chiles Research Institute
  111. Elios Therapeutics
  112. Emergent BioSolutions
  113. Emergent Product Development 
  114. EMMES 
  115. Emory University
  116. Enesi Pharma 
  117. EuBiologics
  118. Federal State Budgetary Scientific Institution
  119. FFF Enterprises
  120. FHI 360
  121. FIT Biotech
  122. Flextronics International
  123. Flinders University
  124. FluGen
  125. Forschungszentrum Jülich
  126. Fourth Military Medical University
  127. Fred Hutchinson Cancer Research Center
  128. Fuda Cancer Hospital
  129. FUJIFILM Pharmaceuticals
  130. Gamaleya Research Institute of Epidemiology and Microbiology
  131. GC Pharma
  132. Genentech
  133. GeneOne Life Science
  134. Genetic Immunity
  135. Genexine
  136. Genocea Biosciences
  137. Georgia Institute of Technology
  138. GeoVax
  139. German Cancer Research Center
  140. Gilead Sciences
  141. GlaxoSmithKline
  142. GlobeImmune
  143. GPO-MBP
  144. Gradalis
  145. Grameen Foundation
  146. Green Cross
  147. GreenSignal Bio Pharma
  148. Gritstone Oncology
  149. Guangdong 999 Brain Hospital
  150. Guangzhou Anjie Biomedical Technology
  151. Guangzhou Trinomab Biotech
  152. Gynecologic Oncology Group
  153. H. Lee Moffitt Cancer Center and Research Institute
  154. Hadassah Medical Organization
  155. Haffkine Bio Pharmaceutical
  156. Hemispherx Biopharma
  157. HIV Vaccine Trials Network
  158. Hookipa Biotech
  159. Hoosier Cancer Research Network
  160. Hualan Biological Bacterin
  161. Ichor Medical Systems
  162. Iconovo
  163. IDRI
  164. Il-Yang Pharmaceutical 
  165. Immatics
  166. Immune Biosolutions
  167. Immune Design
  168. Immunitor
  169. ImmunoCellular Therapeutics
  170. Immunomic Therapeutics
  171. ImmuPatch
  172. Imperial College London
  173. Imugene 
  174. INCYTO
  175. Infectious Disease Research Institute
  176. Innoture Medical Technology
  177. Inovio Pharmaceuticals
  178. Inserm 
  179. Institut Pasteur
  180. Institute of Clinical Research 
  181. Institute of Vaccines and Medical Biologicals
  182. International Centre for Diarrheal Disease Research
  183. International Vaccine Institute
  184. Intravacc
  185. Invectys
  186. IPPOX Foundation 
  187. ISA Pharmaceuticals
  188. Istari Oncology
  189. Janssen Biotech
  190. Japan BCG Laboratory
  191. Jiangsu Jindike Biotechnology
  192. Jiangsu Province Centers for Disease Control and Prevention
  193. Jinan University Guangzhou
  194. JN-International Medical 
  195. Johns Hopkins Bloomberg School of Public Health
  196. Jonsson Comprehensive Cancer Center
  197. Jurong Centers for Disease Control and Prevention
  198. Kenya Medical Research Institute
  199. Korean Center for Disease Control and Prevention
  200. Kurve Technology
  201. Laboratory Corporation of America
  202. Leiden University Medical Center
  203. Leidos
  204. LG Chem
  205. Likang Life Sciences
  206. LimmaTech Biologics
  207. London School of Hygiene and Tropical Medicine
  208. Louisiana State University Health Sciences Center in New Orleans
  209. LTS
  210. Ludwig Institute for Cancer Research
  211. Ludwig-Maximilians-University, Charite University
  212. LuMind Research Down Syndrome Foundation
  213. Madison Vaccines
  214. Mahidol University
  215. Marker Therapeutics
  216. Massachusetts General Hospital
  217. MassBiologics
  218. Mayo Clinic
  219. MCM Vaccine
  220. McMaster University
  221. MD Anderson Cancer Center
  222. Medicago
  223. Medical International Technologies
  224. Medical Research Council
  225. Medical University Innsbruck
  226. Medical University of Vienna
  227. Medigen Vaccine Biologics
  228. MedImmune
  229. MEDRx
  230. MedsForAll
  231. Memorial Sloan Kettering Cancer Center
  232. Mercia Pharma
  233. Merck
  234. Microdermics
  235. Micron Biomedical
  236. Micropoint Technologies
  237. MIKROGEN 
  238. Military Infectious Diseases Research Program
  239. Minervax
  240. Ministry of Health of the Russian Federation
  241. Ministry of Health and Sanitation of Sierra Leone
  242. Moffitt Clinical Research Network
  243. Mogam Biotechnology Research Institute
  244. Moore Medical
  245. MSD Wellcome Trust Hilleman Laboratories
  246. Mundipharma
  247. Mylan
  248. NanoPass Technologies
  249. NantKwest
  250. National Cancer Institute
  251. National Institute for Health Research
  252. National Institute for Medical Research
  253. National Institute of Allergy and Infectious Diseases
  254. National Institute of Biomedical Imaging and Bioengineering 
  255. National Institute on Aging
  256. National Institutes of Health
  257. National Pediatric Cancer Foundation
  258. National University Hospital
  259. Naval Medical Research Center
  260. Nemaura Pharma
  261. Nemera
  262. Neon Therapeutics
  263. Norwegian Institute of Public Health
  264. Nova Immunotherapeutics
  265. Nova Laboratories
  266. Novartis
  267. Novavax
  268. NovInject
  269. Nuance Designs
  270. OncBioMune Pharmaceuticals
  271. OncoPep
  272. OncoTherapy Science
  273. Oncovir
  274. Olymvax Biopharmaceuticals
  275. OptiNose
  276. Organon Teknika
  277. Osaka University
  278. Ospedale San Raffaele
  279. Oswaldo Cruz Foundation
  280. Panacea 
  281. Parexel
  282. PATH
  283. PepTcell
  284. Pfizer
  285. PharmaJet
  286. PHC Injection Device Technologies
  287. Philipps University Marburg Medical Center
  288. Philips Medisize
  289. Picofluidics
  290. Plumbline Life Sciences
  291. Profectus BioSciences
  292. Prometheon Pharma
  293. PROSENEX Ambulatoriumbetriebs
  294. Proswell Medical
  295. Protein Sciences
  296. Providence Cancer Center
  297. Providence Health & Services
  298. PT Bio Farma
  299. Public Health England (PHE)
  300. Queen's University Belfast
  301. Research Foundation for Microbial Diseases of Osaka University
  302. Rising Tide Foundation
  303. Robbins Instruments 
  304. Robert Koch Institut 
  305. Romagnolo Scientific Institute for the Study and Treatment of Tumors
  306. Roswell Park Cancer Institute
  307. Royal Liverpool and Broadgreen University Hospitals NHS Trust
  308. Russian Academy of Sciences
  309. Sanaria
  310. Sanofi 
  311. Scandinavian Biopharma
  312. Sellas Life Sciences Group
  313. Sementis
  314. Seqirus
  315. Serum Institute of India
  316. Shanghai Bovax Biotechnology
  317. Shanghai Houchao Biotechnology 
  318. Shantha Biotechnics
  319. Shenzhen Geno-Immune Medical Institute
  320. Shin Nippon Biomedical Laboratories
  321. SHL Group
  322. Sidney Kimmel Comprehensive Cancer Center 
  323. Sinovac Biotech
  324. SK Bioscience
  325. Skinject
  326. Stand Up To Cancer
  327. Stanford University
  328. Statens Serum Institut
  329. Stevanato Group
  330. Swiss Group for Clinical Cancer Research
  331. Takeda
  332. Task Foundation 
  333. Teva Pharmaceutical
  334. Texas Children's Hospital
  335. The Aurum Institute 
  336. The Clatterbridge Cancer Center
  337. The First Affiliated Hospital of Guangdong Pharmaceutical University
  338. The Immunobiological Technology Institute
  339. The Methodist Hospital System 
  340. The Wistar Institute
  341. Themis Bioscience
  342. TheraJect
  343. Third Military Medical University
  344. Transgene
  345. Treos Bio
  346. Trudell Medical International
  347. TuBerculosis Vaccine Initiative
  348. UbiVac
  349. Union Medico
  350. United States Agency for International Development 
  351. United States Army Medical Research Institute of Infectious Diseases
  352. United States Department of Defense
  353. University Health Network
  354. University Hospital Tuebingen 
  355. University Medical Center Hamburg-Eppendorf
  356. University Medical Center Groningen
  357. University of Arkansas
  358. University of California
  359. University of Cape Town Lung Institute
  360. University of Cologne
  361. University of Copenhagen
  362. University of Florida
  363. University of Groningen
  364. University of Iowa
  365. University of Lausanne Hospitals
  366. University of Liverpool
  367. University of Maryland
  368. University of Michigan
  369. University of Oxford
  370. University of Pennsylvania
  371. University of Pisa
  372. University of Pittsburgh
  373. University of South Australia
  374. University of Southampton
  375. University of Sydney
  376. University of Washington
  377. University of Wisconsin
  378. University of Zaragoza
  379. US Army Medical Research and Material Command
  380. Vaccibody
  381. Vaccitech
  382. Valeritas
  383. Valneva
  384. Vaxart
  385. Vaxess Technologies
  386. VAXIMM
  387. Vaxine
  388. Vaxxas
  389. VBI Vaccines
  390. Vetter Pharma
  391. ViciniVax
  392. ViroStatics
  393. Walter Reed Army Institute of Research
  394. Washington University School of Medicine
  395. Weill Medical College of Cornell University
  396. West Pharmaceuticals
  397. World Health Organization 
  398. World Vision of Ireland
  399. Wyeth Pharmaceuticals
  400. XEME Biopharma
  401. Xiamen Innovax Biotech
  402. Xiamen University
  403. Ypsomed
  404. Zosano Pharma

Request Customization

Please select a suitable option for customization in the report

PRICING DETAILS

USD 4,499

This license grants the right of use of the purchased report to a single recipient only (normally the person who buys the report). You may access the material on your computer, as and when required, for your own personal use. You may also print read more

This license grants the right of use of the purchased report by the employees of a business unit at a particular site / office location. The report may be accessed on the computer of any employee within the business unit. You may also print multiple read more

This license entitles the buyer of the report to share, distribute the report (either full or in part) with other employees of the same firm / enterprise. The report may be accessed by any employee of the enterprise and there is no limit on the read more

Discounts available for multiple report purchases
sales@rootsanalysis.com